Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Daniel Pietrasz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0643-9917; OpenAlex author ID A5055837353. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 21

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-025-13160-7↗
  3. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  4. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  5. Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma? First author DOI 10.1016/j.dld.2022.01.126↗
  6. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  7. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-022-01745-2↗
  8. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
  9. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. Co-author DOI 10.1158/1078-0432.ccr-21-1907↗
  10. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  11. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Co-author DOI 10.1016/j.ctrv.2020.102028↗
  12. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Co-author DOI 10.3390/cancers12123866↗
  13. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… Co-author DOI 10.1016/j.clinre.2019.03.007↗
  14. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1038/s41598-019-53271-6↗
  15. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  16. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Co-author DOI 10.1158/0008-5472.can-15-2790↗
  17. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Co-author DOI 10.1007/s00018-017-2579-9↗
  18. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-016-4632-8↗
  19. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Co-author DOI 10.1158/1078-0432.ccr-16-0806↗
  20. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  21. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 16 shared papers, 2015–2025 · strength 1.61
  2. Pierre Laurent‐Puig · 7 shared papers, 2017–2025 · strength 0.92
  3. Solène Doat · 5 shared papers, 2017–2025 · strength 0.74
  4. Olivier Caliez · 3 shared papers, 2021–2025 · strength 0.55
  5. António Sá Cunha · 6 shared papers, 2015–2025 · strength 0.49
  6. Julien Taı̈eb · 5 shared papers, 2015–2022 · strength 0.43
  7. Roberto Salvia · 3 shared papers, 2020–2025 · strength 0.39
  8. Mathilde Wagner · 3 shared papers, 2015–2025 · strength 0.38
  9. Léo Mas · 2 shared papers, 2020–2025 · strength 0.38
  10. Pascal R. Hammel · 2 shared papers, 2020–2021 · strength 0.26
  11. Isabelle Trouilloud · 3 shared papers, 2015–2021 · strength 0.24
  12. Claudio Bassi · 2 shared papers, 2020–2022 · strength 0.23
  13. Shulin Zhao · 2 shared papers, 2020–2021 · strength 0.23
  14. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  15. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  16. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  17. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  18. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  19. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  20. Johan Gagnière · 2 shared papers, 2020–2025 · strength 0.22
  21. Stijn R. van Roessel · 2 shared papers, 2020–2025 · strength 0.22
  22. Frederik Christiaan Berrevoet · 2 shared papers, 2020–2025 · strength 0.22
  23. Kevin C. Conlon · 2 shared papers, 2020–2025 · strength 0.22
  24. Eran van Veldhuisen · 2 shared papers, 2020–2025 · strength 0.22
  25. Thilo Hackert · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.